Brickell is focused on the development of novel and differentiated therapies for the treatment of skin diseases.

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases. Our current pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, cutaneous t-cell lymphoma and psoriasis.

» READ MORE

Latest News

[February 20, 2018]

Brickell Announces Confirmatory Phase 2b Study Results Presented at the 76th American Academy of Dermatology Annual Meeting at the Late-Breaking Research Forum.

» READ ARTICLE


[October 24, 2017]

Brickell Announces Positive, Statistically Significant Results of its Confirmatory Phase 2b Study of Sofpironium Bromide for the Topical Treatment of Primary Axillary Hyperhidrosis.

» READ ARTICLE